TMCI — Treace Medical Concepts Income Statement
0.000.00%
Last trade - 00:00
- $644.13m
- $573.94m
- $187.12m
- 32
- 24
- 39
- 23
2019 December 31st | 2020 December 31st | C2021 December 31st | C2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 39.4 | 57.4 | 94.4 | 142 | 187 |
Cost of Revenue | |||||
Gross Profit | 31.8 | 44.9 | 77.5 | 116 | 152 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 43 | 56.5 | 111 | 181 | 239 |
Operating Profit | -3.54 | 0.855 | -16.5 | -39.6 | -51.4 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -4.26 | -3.67 | -20.6 | -42.8 | -49.5 |
Net Income After Taxes | -4.26 | -3.67 | -20.6 | -42.8 | -49.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.26 | -3.67 | -20.6 | -42.8 | -49.5 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.91 | -4.31 | -20.7 | -42.8 | -49.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.097 | -0.085 | -0.429 | -0.688 | -0.814 |
Dividends per Share |